ESR1 and breast cancer: In spite of these marked therapeutic advances, the most aggressive basal-like tumors, which largely overlap with the triple ER, PR and HER2 negative subtype of breast cancer (TNBC), continue to present a significant clinical challenge due to the limited availability of treatment options [2, 3].